LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9 | -18.2% | 8 | 0.0% | 0.00% | – |
| Q2 2023 | $11 | -8.3% | 8 | 0.0% | 0.00% | – |
| Q1 2023 | $12 | +33.3% | 8 | 0.0% | 0.00% | – |
| Q4 2022 | $9 | – | 8 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 8 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 8 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $55,198,000 | 4.16% |
| Raffles Associates | 1,930,536 | $3,050,000 | 3.32% |
| Defender Capital, LLC. | 5,131,935 | $8,108,000 | 3.18% |
| Prescott General Partners LLC | 1,851,851 | $2,926,000 | 0.20% |
| DAFNA Capital Management LLC | 140,000 | $221,000 | 0.06% |
| Laurion Capital Management LP | 2,422,367 | $3,827,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $71,000 | 0.05% |
| Fort Sheridan Advisors LLC | 78,931 | $125,000 | 0.04% |
| Long Focus Capital Management, LLC | 215,000 | $340,000 | 0.04% |
| MORGAN JESS S & CO INC | 20,000 | $32,000 | 0.03% |